Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 13, 2020
CHMP Gives Positive Opinion on Centus Biotherapeutics’ Bevacizumab Biosimilar
Author(s)Pharmaceutical Technology Editors
The committee has given a positive opinion on the biosimilar bevacizumab for several cancer indications.
Advertisement
Centus Biotherapeutics, a joint venture between AstraZeneca and Fujifilm Kyowa Kirin Biologics, has received a positive opinion from the European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) for Equidacent, a biosimilar to Avastin (bevacizumab), Roche’s innovator biologic. Avastin is Roche’s top-selling drug, earning approximately CHF $7 billion (US$7.6 billion) in 2019 sales (1).
The positive opinion applies to the use of Equidacent for treating several cancers, including metastatic carcinoma of the colon or rectum; metastatic breast cancer; unresectable advanced, metastatic or recurrent non-small cell lung cancer; advanced and/or metastatic renal cell cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer; and persistent, recurrent, or metastatic carcinoma of the cervix, Centus announced in a July 27, 2020 press release.
A decision on the marketing authorization application for the drug is expected to be delivered by the European Commission in September 2020. If approved, Equidacent will be authorized for use in the 27 European Union member countries, the United Kingdom, and the European Economic Area member states of Norway, Iceland, and Liechtenstein.
"We are very happy receiving a positive CHMP opinion toward approval of Equidacent, our bevacizumab biosimilar. We will continue with every effort to bring Equidacent to patients and healthcare professionals," said Hiroshi Ohashi from Fujifilm Kyowa Kirin Biologics, who serves as president and product development team at Centus, in the company press release.
"This represents a great collaborative effort between our shareholders to bring high quality and affordable medicines to our patients worldwide," added Kelvin Tsang from AstraZeneca, who serves as product development team co-lead at Centus, in the press release.
Reference
1. Roche, “Finance Report 2019,” roche.com/investors, March 2020.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement